Quick Answer
Silence Therapeutics plc reported Stockholders Equity of $62.30 million for the year ending 2025.
- Silence Therapeutics plc showed a decrease of -53.5% in Stockholders Equity from 2024 to 2025.
- This data is from Silence Therapeutics plc's annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $156.76 million | Q2 2024: $142.53 million | Q3 2024: $126.70 million | Q1 2025: $112.74 million | Q2 2025: $94.16 million | Q3 2025: $74.06 million.
- Over the full 5 years of available data (2021 to 2025), Silence Therapeutics plc's Stockholders Equity has grown by 403.5%.
- Historical annual values: Fiscal year 2025: $62.30 million | Fiscal year 2024: $134.02 million | Fiscal year 2023: $21.99 million | Fiscal year 2022: $27.22 million | Fiscal year 2021: $12.37 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: